Aurobindo Pharma gets USFDA nod to market potassium chloride pills in US

Representative Image

Aurobindo Pharma Ltd Friday said it has got the approval of the US Food and Drug Administration (USFDA) to make and market potassium chloride tablets of 600 mg and 750 mg for the US market.

The tablet, a generic version of Upsher-Smith's Klor-Con extended release tablets, would be launched next month, said a press release here.

The potassium chloride tablets are for treating hypokalemia, a condition wherein there is a drop in the potassium-level in the blood.

The drug has an estimated market size of USD 60 million for 12 months ending October 2018, the release said quoting market reports.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel